Aktis Oncology opened lower at $16.99, compared with its previous close of $17.04. In the last trading session, the stock traded between $16.33 and $16.99. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Aktis Oncology is now worth
$ 208.24
Giving a profit of
$ 108.24 (108.24%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.74 (-4.31%)
Day High
$16.99
Day Low
$16.33
Day Open
$16.99
Prev Close
$17.04
Volume
1,99,132
1W Return
7.33%
1M Return
-6.02%
3M Return
-34.12%
6M Return
-10.76%
1Y Return
-27.21%
Fundamentals
Market Cap ($ Mn)
876
PE Ratio
-
PB Ratio
2.94
PEG Ratio
-
ROE
-
ROCE
-28.27%
EPS (TTM)
-
Investment Returns
1 Week
7.33%
1 Month
-6.02%
3 Months
-34.12%
6 Months
-10.76%
9 Months
-9.72%
Financials
Quarterly
All values in $ Mn
1.4
Mar 25
1.6
Jun 25
1.6
Sep 25
1.9
Dec 25
3.2
Mar 26
3.4
Jun 26
Updates
12Nov
Aktis Oncology Q3 Results: EPS miss widens loss to $(0.54)
Aktis Oncology reported a quarterly loss of $(0.54) per share, missing the $(0.48) analyst estimate. Quarterly revenue grew 147.31% YoY to $3.905 million but missed the $4.016 million consensus. The loss per share expanded 97.18% compared to the $(19.18) loss recorded in the same period last year.
Aktis Oncology reported Q2 2026 results with a net loss of $24.1 million and EPS of $(0.44), missing the $(0.43) estimate. However, revenue of $3.384 million beat the $2.000 million consensus by 69%. Cash reserves increased to $517.3 million following the January 2026 IPO, supporting operations through 2029.
3mo ago
14Jul
JP Morgan raises Aktis Oncology price target to $33
JP Morgan analyst Jessica Fye maintained an Overweight rating on Aktis Oncology (NASDAQ: AKTS) and raised the price target to $33 from $30.
4mo ago
16Jun
Raymond James initiates coverage on Aktis Oncology with Strong Buy rating
Raymond James analyst Christopher Raymond initiated coverage on Aktis Oncology with a Strong Buy rating and a price target of $40. The NASDAQ-listed stock closed at $20.69 on Monday.
